designer491
designer491 / iStockphoto.com
15 November 2017Americas

Excision Bio licenses CRISPR technology from UC Berkeley

Excision BioTherapeutics has become the first company to secure exclusive licences from the University of California (UC), Berkeley for “newly discovered” CRISPR gene editors.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
28 March 2017   The European Patent Office has revealed its intention to grant a patent covering the CRISPR gene-editing technology to the University of California, Berkeley, the University of Vienna, and inventor Emmanuelle Charpentier.
Americas
31 July 2017   The University of California, Berkeley has filed a brief at the US Court of Appeals for the Federal Circuit in its appeal against a patent decision on the CRISPR/Cas9 technology.

More on this story

Americas
28 March 2017   The European Patent Office has revealed its intention to grant a patent covering the CRISPR gene-editing technology to the University of California, Berkeley, the University of Vienna, and inventor Emmanuelle Charpentier.
Americas
31 July 2017   The University of California, Berkeley has filed a brief at the US Court of Appeals for the Federal Circuit in its appeal against a patent decision on the CRISPR/Cas9 technology.

More on this story

Americas
28 March 2017   The European Patent Office has revealed its intention to grant a patent covering the CRISPR gene-editing technology to the University of California, Berkeley, the University of Vienna, and inventor Emmanuelle Charpentier.
Americas
31 July 2017   The University of California, Berkeley has filed a brief at the US Court of Appeals for the Federal Circuit in its appeal against a patent decision on the CRISPR/Cas9 technology.